Inborn Errors of Immunity in Algerian Children and Adults: A Single-Center Experience Over a Period of 13 Years (2008-2021).
Algeria
clinical features
diagnosis
epidemiology
inborn errors of immunity
molecular diagnosis
primary immunodeficiency
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
03
2022
accepted:
25
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Inborn errors of immunity (IEI) predispose patients to various infectious and non-infectious complications. Thanks to the development and expanding use of flow cytometry and increased awareness, the diagnostic rate of IEI has markedly increased in Algeria the last decade. This study aimed to describe a large cohort of Algerian patients with probable IEI and to determine their clinical characteristics and outcomes. We collected and analyzed retrospectively the demographic data, clinical manifestations, immunologic, genetic data, and outcome of Algerian IEI patients - diagnosed in the department of medical immunology of Beni Messous university hospital center, Algiers, from 2008 to 2021. Eight hundred and seven patients with IEI (482 males and 325 females) were enrolled, 9.7% of whom were adults. Consanguinity was reported in 50.3% of the cases and a positive family history in 32.34%. The medium age at disease onset was 8 months and at diagnosis was 36 months. The median delay in diagnosis was 16 months. Combined immunodeficiencies were the most frequent (33.8%), followed by antibody deficiencies (24.5%) and well-defined syndromes with immunodeficiency (24%). Among 287 patients tested for genetic disorders, 129 patients carried pathogenic mutations; 102 having biallelic variants mostly in a homozygous state (autosomal recessive disorders). The highest mortality rate was observed in patients with combined immunodeficiency (70.1%), especially in patients with severe combined immunodeficiency (SCID), Omenn syndrome, or Major Histocompatibility Complex (MHC) class II deficiency. The spectrum of IEI in Algeria is similar to that seen in most countries of the Middle East and North Africa (MENA) region, notably regarding the frequency of autosomal recessive and/or combined immunodeficiencies.
Sections du résumé
Background
Inborn errors of immunity (IEI) predispose patients to various infectious and non-infectious complications. Thanks to the development and expanding use of flow cytometry and increased awareness, the diagnostic rate of IEI has markedly increased in Algeria the last decade.
Aim
This study aimed to describe a large cohort of Algerian patients with probable IEI and to determine their clinical characteristics and outcomes.
Methods
We collected and analyzed retrospectively the demographic data, clinical manifestations, immunologic, genetic data, and outcome of Algerian IEI patients - diagnosed in the department of medical immunology of Beni Messous university hospital center, Algiers, from 2008 to 2021.
Results
Eight hundred and seven patients with IEI (482 males and 325 females) were enrolled, 9.7% of whom were adults. Consanguinity was reported in 50.3% of the cases and a positive family history in 32.34%. The medium age at disease onset was 8 months and at diagnosis was 36 months. The median delay in diagnosis was 16 months. Combined immunodeficiencies were the most frequent (33.8%), followed by antibody deficiencies (24.5%) and well-defined syndromes with immunodeficiency (24%). Among 287 patients tested for genetic disorders, 129 patients carried pathogenic mutations; 102 having biallelic variants mostly in a homozygous state (autosomal recessive disorders). The highest mortality rate was observed in patients with combined immunodeficiency (70.1%), especially in patients with severe combined immunodeficiency (SCID), Omenn syndrome, or Major Histocompatibility Complex (MHC) class II deficiency.
Conclusion
The spectrum of IEI in Algeria is similar to that seen in most countries of the Middle East and North Africa (MENA) region, notably regarding the frequency of autosomal recessive and/or combined immunodeficiencies.
Identifiants
pubmed: 35529857
doi: 10.3389/fimmu.2022.900091
pmc: PMC9069527
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
900091Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127564
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI095983
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Informations de copyright
Copyright © 2022 Belaid, Lamara Mahammed, Drali, Oussaid, Touri, Melzi, Dehimi, Berkani, Merah, Larab, Allam, Khemici, Kirane, Boutaba, Belbouab, Bekkakcha, Guedouar, Chelali, Baamara, Noui, Baaziz, Rezak, Azzouz, Aichaoui, Moktefi, Benhatchi, Oussalah, Benaissa, Laredj, Bouchetara, Adria, Habireche, Tounsi, Dahmoun, Touati, Boucenna, Bouferoua, Sekfali, Bouhafs, Aboura, Kherra, Inouri, Dib, Medouri, Khelfaoui, Redjedal, Zelaci, Yahiaoui, Medjadj, Touhami, Kadi, Amireche, Frada, Houasnia, Benarab, Boubidi, Ferhani, Benalioua, Sokhal, Benamar, Aggoune, Hadji, Bellouti, Rahmoune, Boutrid, Okka, Ammour, Saadoune, Amroun, Belhadj, Ghanem, Abbaz, Boudrioua, Zebiche, Ayad, Hamadache, Ouaras, Achour, Bouchair, Boudiaf, Bekkat-Berkani, Maouche, Bouzrar, Aissat, Ibsaine, Bioud, Kedji, Dahlouk, Bensmina, Radoui, Bessahraoui, Bensaadi, Mekki, Zeroual, Chan, Leung, Tebaibia, Ayoub, Mekideche, Gharnaout, Casanova, Puel, Lau, Cherif, Ladj, Smati, Boukari, Benhalla and Djidjik.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Pediatr. 2019 Jan 3;19(1):1
pubmed: 30606158
Front Immunol. 2020 Aug 06;11:1491
pubmed: 32849507
Clin Exp Immunol. 2014 Dec;178 Suppl 1:18-20
pubmed: 25546747
J Clin Immunol. 2007 Sep;27(5):497-502
pubmed: 17577648
Ann N Y Acad Sci. 2011 Nov;1238:42-52
pubmed: 22129052
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
J Clin Immunol. 2013 Jan;33(1):1-7
pubmed: 22847546
J Pediatr. 2018 Mar;194:211-217.e5
pubmed: 29198545
Front Immunol. 2017 Jun 27;8:737
pubmed: 28702026
Immunol Allergy Clin North Am. 2020 Aug;40(3):385-402
pubmed: 32654688
J Clin Immunol. 2013 Jan;33(1):74-83
pubmed: 22983506
J Clin Immunol. 2011 Jun;31(3):297-308
pubmed: 21243521
Front Immunol. 2019 Jul 19;10:1272
pubmed: 31379802
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Clin Exp Immunol. 2015 Oct;182(1):45-50
pubmed: 26031847
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651211
J Community Genet. 2016 Jan;7(1):65-79
pubmed: 26363620
J Allergy Clin Immunol. 2018 Mar;141(3):1036-1049.e5
pubmed: 29241729
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Clin Exp Immunol. 2009 Sep;157 Suppl 1:3-11
pubmed: 19630863
Reprod Health. 2009 Jan 06;6:1
pubmed: 19126239
J Clin Immunol. 2011 Feb;31(1):99-105
pubmed: 20859665
Front Immunol. 2018 May 14;9:636
pubmed: 29867916
Front Immunol. 2020 Jan 22;10:3148
pubmed: 32038648
Front Immunol. 2019 Jul 24;10:1754
pubmed: 31396239
BMC Res Notes. 2017 Jan 3;10(1):1
pubmed: 28057050
Front Immunol. 2020 Aug 13;11:1605
pubmed: 32903579